{
    "Trade/Device Name(s)": [
        "Pointe Scientific Cocaine Metabolite Enzyme Immunoassay"
    ],
    "Submitter Information": "MedTest Dx",
    "510(k) Number": "K191638",
    "Predicate Device Reference 510(k) Number(s)": [
        "K113139"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DIO"
    ],
    "Summary Letter Date": "January 27, 2020",
    "Summary Letter Received Date": "January 28, 2020",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.3250"
    ],
    "Regulation Name(s)": [
        "Cocaine And Cocaine Metabolite Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Benzoylecgonine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        "Mindray BS-480",
        "Mindray BA-800M"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)",
        "Spectrophotometric detection"
    ],
    "Methodologies": [
        "Competitive enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Pointe Scientific Cocaine Metabolite Enzyme Immunoassay, a qualitative assay for benzoylecgonine in human urine using enzyme immunoassay technology.",
    "Indications for Use Summary": "Qualitative determination of benzoylecgonine (a cocaine metabolite) in human urine at a cutoff value of 150 ng/mL; provides preliminary analytical test result, confirmatory testing required.",
    "fda_folder": "Toxicology"
}